Orexigen Therapeutics, Inc. to Present Data on Contrave(TM) and Empatic(TM) at The Obesity Society's 2007 Annual Scientific Meeting

SAN DIEGO--(BUSINESS WIRE)--Orexigen™ Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders including obesity, today announced that the Company will be presenting data on its two product candidates for the treatment of obesity, ContraveTM and EmpaticTM, in five sessions at The Obesity Society’s Annual Scientific Meeting (NAASO) in New Orleans, October 20-24, 2007.